Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Windtree Therapeutics Inc

Company price
0.0003 USD 0.00 ( 50.00%)
Last update at 2026-11-17T21:00:00Z
VOLUME
70000
Market Cap
0.01M

Momentum Score

…

Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. Its lead product candidate is istaroxime, which is in Phase 2b clinical trials for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. The company also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trials to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant for the treatment of respiratory disease, disorder, or condition in humans; Rostafuroxin, which is in Phase 2b clinical trials for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activators, which are in preclinical trials for the treatment of chronic and acute heart failure. In addition, it is developing an aPKCi inhibitor, which is in preclinical trials for the treatment of cutaneous malignancies and solid tumors. Windtree Therapeutics, Inc. has a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; a license, development, and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; a license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and a collaboration with Battelle Memorial Institute for the development of its aerosol delivery system. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was founded in 1992 and is headquartered in Warrington, Pennsylvania.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.00
Low
0.01
High
52 Week Price Range
0.00
Low
0.19
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
0.00
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
-17.79M
Debt / Equity
0.18
ROE
-412.90%
Net Debt
0.04M
ROCE
-7.03%
Diluted EPS TTM
8.08

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -1.79M -20.29M -40.58M -77.62M -32.57M
Net income -5.49M -20.29M -39.21M -67.64M -30.28M
Selling general administrative 8.74M 0.01M 10.79M 14.47M 14.94M
Selling and marketing expenses - 9.19M - - -
Gross profit -0.08M -0.08M - - -
Reconciled depreciation 0.08M 0.08M 0.53M 0.19M 0.17M
Ebit -1.56M -20.24M -41.33M -77.28M -30.32M
Ebitda -1.47M -20.16M -21.08M -32.49M -32.44M
Depreciation and amortization 0.08M 0.08M 20.25M 44.79M -2.12M
Non operating income net other - - - - -2.12M
Operating income -25.02M -17.54M -41.33M -77.28M -30.32M
Other operating expenses 25.02M 17.54M 21.89M 32.26M 30.32M
Interest expense 0.23M 0.05M 0.05M 0.11M 0.12M
Tax provision -0.01M 0.00M -1.37M -9.99M -
Interest income 0.07M 0.33M 0.11M 0.09M 0.12M
Net interest income -0.17M 0.28M 0.06M -0.02M -0.00M
Income tax expense 3.69M -0.09M -1.37M -9.99M -2.29M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 24.93M 17.46M 21.89M 32.26M 30.32M
Cost of revenue 0.08M 0.08M - - -
Total other income expense net 23.23M -2.75M 0.76M -0.34M -2.25M
Net income from continuing ops -1.79M -20.29M -39.21M -67.64M -32.57M
Net income applicable to common shares - - - -67.64M -32.57M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 27.88M 32.41M 37.95M 74.79M 112.89M
Intangible assets 24.13M 25.25M 25.25M 32.07M 77.09M
Other current assets 0.80M 1.06M 1.21M 1.14M 1.19M
Total liab 17.88M 29.02M 27.94M 32.91M 43.33M
Total stockholder equity 10.00M 3.39M 10.01M 41.88M 69.55M
Deferred long term liab - - - - 16.78M
Other current liab 2.41M 2.52M 1.55M 3.41M 3.81M
Common stock 0.30M 0.01M - 0.03M 0.02M
Capital stock 0.00M 0.01M 0.00M 0.03M 0.02M
Retained earnings -846.61M -844.82M -824.53M -785.32M -717.69M
Other liab - - - 10.91M 19.58M
Good will - 0.00M 3.06M 15.68M 15.68M
Other assets - 0.00M - 0.15M 0.15M
Cash 1.78M 4.32M 6.17M 22.35M 16.93M
Total current liabilities 5.72M 4.00M 2.46M 4.92M 6.13M
Net debt 0.04M 12.51M -3.89M -19.45M -13.15M
Short term debt 1.17M 0.67M 0.66M 0.82M 1.16M
Short long term debt 0.66M 0.23M 0.25M 0.29M 0.35M
Short long term debt total 1.82M 16.83M 2.28M 2.89M 3.78M
Other stockholder equity 856.61M 848.21M 834.54M 827.18M 787.22M
Property plant equipment - - - 3.39M 1.84M
Total current assets 2.57M 5.38M 7.38M 23.49M 18.12M
Net tangible assets - - - -5.87M -23.22M
Long term debt - - - - 2.42M
Accounts payable 1.88M 0.81M 0.25M 0.69M 1.16M
Accumulated other comprehensive income 0.00M 0.00M - - -
Common stock total equity - - - - 0.02M
Retained earnings total equity - - - - -717.69M
Treasury stock - - - - -3.05M
Non currrent assets other 0.01M 0.15M 0.15M 0.15M 0.15M
Non current assets total 25.30M 27.03M 30.58M 51.30M 94.77M
Capital lease obligations 1.16M 1.60M 2.03M 2.60M 1.01M
Long term debt total - - - - 2.42M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments -0.01M -0.01M 0.20M -0.28M -0.29M
Change to liabilities - - - -0.47M -0.55M
Total cashflows from investing activities -0.01M -0.01M - -0.28M -0.29M
Net borrowings 1.26M -0.80M - -3.87M -3.23M
Total cash from financing activities 12.73M 11.60M 3.08M 29.36M 19.96M
Change to operating activities - - - 0.41M -0.78M
Net income -1.79M -20.29M -39.21M -67.64M -32.57M
Change in cash -2.68M -1.86M -16.18M 5.42M -5.65M
Begin period cash flow 4.47M 6.33M 22.50M 17.08M 22.73M
End period cash flow 1.79M 4.47M 6.33M 22.50M 17.08M
Total cash from operating activities -15.40M -13.44M -19.45M -23.66M -25.32M
Issuance of capital stock 5.49M 11.55M 4.25M 32.23M 20.25M
Depreciation 0.08M 0.08M 0.53M 0.19M 0.17M
Dividends paid 0.66M 0.00M - - -
Sale purchase of stock -1.88M 0.00M - - 20.39M
Other cashflows from financing activities 6.65M 0.84M 0.20M 1.00M 3.49M
Change to netincome - - - 43.84M 8.41M
Capital expenditures 0.01M 0.01M 0.01M 0.28M 0.29M
Cash flows other operating - - - - -0.89M
Cash and cash equivalents changes - - - - -5.65M
Change in working capital 1.37M 2.02M -1.78M -0.06M -1.33M
Stock based compensation 0.46M 1.28M 3.09M 7.24M 5.68M
Other non cash items -15.31M 3.48M 19.28M 46.59M 1.59M
Free cash flow -15.41M -13.45M -19.46M -23.94M -25.61M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
WINT
Windtree Therapeutics Inc
0.00
50.00%
0.00 - 0.37 660.53 0.61 706.08 0.01
NVO
Novo Nordisk A/S
-0.34
0.86%
39.09 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-6.95
1.30%
529.50 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
-18.50
1.96%
927.03 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Windtree Therapeutics Inc

Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. Its lead product candidate is istaroxime, which is in Phase 2b clinical trials for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. The company also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trials to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant for the treatment of respiratory disease, disorder, or condition in humans; Rostafuroxin, which is in Phase 2b clinical trials for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activators, which are in preclinical trials for the treatment of chronic and acute heart failure. In addition, it is developing an aPKCi inhibitor, which is in preclinical trials for the treatment of cutaneous malignancies and solid tumors. Windtree Therapeutics, Inc. has a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; a license, development, and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; a license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and a collaboration with Battelle Memorial Institute for the development of its aerosol delivery system. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was founded in 1992 and is headquartered in Warrington, Pennsylvania.

2600 Kelly Road, Warrington, PA, United States, 18976-3622

215 488 9300

14

Name Title Year Born
Mr. Craig E. Fraser Pres, CEO & Director 1965
Mr. John P. Hamill CPA Sr. VP, CFO, Treasurer & Corp. Sec. 1964
Dr. Steven G. Simonson Sr. VP & Chief Medical Officer 1959
Mr. Eric L. Curtis M.B.A. Sr. VP & COO 1969
Mr. George Cox VP of Technical Operations 1952
Ms. Diane Carman Esq. Sr. VP & Gen. Counsel 1969
Dr. Pratap Paruchuru Exec. Director of Clinical Devel. NA
Ms. Tracy Rarick Head of Operations & Program Management NA
Dr. Ronald L. Dundore Exec. Director of Regulatory Affairs & Quality 1955
Mr. Craig E. Fraser Chairman, President, CEO & Interim Principal Officer 1965

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…